ArticleNoro psikiyatri arsivi2025
Clinical and Laboratory Characteristics of Patients with Neurosarcoidosis.
Article in Noro psikiyatri arsivi, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Psychiatric manifestation of neurosarcoidosis: a systematic review with pooled descriptive analysis of case reports and case series.Rheumatology international · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Neurosarcoidosis (NS) represents the most severe complication of sarcoidosis. NS exhibits a diverse array of clinical and radiological features that mimic many inflammatory, infectious, and neoplastic neurological disorders. In our study, we evaluated the demographic, clinical, laboratory, and imaging features of patients with NS. Methods: In this retrospective observational study, we included patients with definite and probable NS with at least 6-months of follow-up. Diagnostic tests, including cerebrospinal fluid analysis and imaging findings, lesion localization, therapeutic interventions, and disease course were evaluated. The modified Rankin scale was employed as a metric to assess the severity of the disease. Results: Fourteen patients met the inclusion criteria; two were definitively diagnosed with NS through brain biopsy, while twelve received a probable NS diagnosis based on biopsies of non-neuronal tissues. The predominant initial manifestation of NS was cranial neuropathy (64.3%), with facial palsy emerging as the most prevalent subset (35.7%). Five patients exhibited parenchymal involvement, while leptomeningeal involvement was noted in two. All patients were treated with corticosteroids, with nine individuals (64.3%) necessitating additional immunosuppressive interventions. Stable disease or improvement was observed in the majority of patients (85.7%), albeit one case resulted in mortality. Conclusion: We observed favorable outcomes in the majority of patients. Nevertheless, it's imperative to acknowledge that NS can lead to both mortality and severe morbidity. Recognizing clinical patterns is vital for accurate diagnosis and effective treatment. However, there is an existing gap in management, underscoring the necessity for randomized controlled trials aimed at elucidating optimal treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.